Matrix metalloproteinases in neoplasm-induced extracellular matrix remodeling in breast carcinomas

Anticancer Research

Volumn 21, Issue 3 B, 2001, Pages 2021-2028

  Bodey, B ^a   Bodey B , Jr ^a   Siegel, S E ^a   Kaiser, H E ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Breast carcinoma (BC); Cellular dedifferentiation; Extracellular Matrix (ECM); Immunohistochemistry; Matrix metalloproteinases (MMPs); Metastasis; Monoclonal antibodies (MoABs); Neoplastic cell invasion; Progression of the neoplastic cellular immunophenotype; Tumor cell tissue stroma interaction

Indexed keywords

ALKALINE PHOSPHATASE; BIOTIN; COLLAGENASE 3; CYTOKINE; GELATINASE A; GELATINASE B; GROWTH FACTOR; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; STREPTAVIDIN; STROMELYSIN; STROMELYSIN 2;

ARTICLE; BREAST CARCINOGENESIS; BREAST CARCINOMA; CANCER GROWTH; CELL CLONING; CELL MIGRATION; CLINICAL ARTICLE; CONTROLLED STUDY; EXTRACELLULAR MATRIX; HUMAN; HUMAN TISSUE; IMMUNOPHENOTYPING; IMMUNOREACTIVITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEQUENCE HOMOLOGY;

ALKALINE PHOSPHATASE; BIOTIN; BREAST NEOPLASMS; CELL MOVEMENT; EXTRACELLULAR MATRIX; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MATRIX METALLOPROTEINASE 10; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 3; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; METALLOENDOPEPTIDASES; STREPTAVIDIN;

EID: 0034898282     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (98)

1. Reduction of homozygosity of genes on chromosome 11 in human breast neoplasia
2. Refinement of regional loss of heterozygosity for chromosome 11p15.5 in human breast tumors
3. Loss of heterozygosity at 11q22-q23 in breast cancer
4. Loss of heterozygosity in sporadic human breast carcinoma a common region between 11q22 and 11q23.3
5. Loss of heterozygosity for chromosome 11 in primary human breast tumors is associated with poor survival after metastasis
6. Distal deletion of chromosome 1p in ductal carcinoma of the breast
7. Loss of heterozygosity on chromosome 1q in human breast cancer
8. Presence of two members of c-erbA receptor gene family (c-erbA and c-erbA2) in smallest region of somatic homozygosity on chromosome 3p21-25 in human breast carcinoma
9. Allelotype of human breast carcinoma: A second major site for loss of heterozygosity is on chromosome 6q
10. Loss of heterozygosity in chromosome 7q and aggressive primary breast cancer
11. Loss of heterozygosity in human ductal breast tumors indicates a recessive mutation on chromosome 13
12. Loss of heterozygosity on chromosome 17 and 18 in breast carcinoma: Two additional regions identified
13. Allelotype of breast cancer: Cumulative allele losses promote tumor progression in primary breast cancer
14. Comparative allelotype of in situ and invasive human breast cancer: High frequency of microsatellite instability in lobular breast carcinoma
15. Purification and properties of a gelatin-specific neutral protease from human skin
16. Cleavage of type VII collagen by interstitial collagenase and type IV collagenase (gelatinase) derived from human skin
17. Cleavage specificity of human skin type IV collagenase (gelatinase). Identification of cleavage sites in type I gelatin, with confirmation using synthetic peptides
18. Cleavage of collagen type X by human synovial collagenase and neutrophil elastase
19. Differential susceptibility of type X collagen to cleavage by two mammalian interstitial collagenase and 72-kDa type IV collagenase
20. Human 92- and 72-kilodalton type IV collagenases are elastases
21. Expression of a metalloproteinase that degrades native type V collagen and denatured collagens by cultured human alveolar macrophages
22. A 92 kDa gelatinase (MMP-9) cleavage site in native type V collagen
23. Relation between substrate specificity and domain structure of 92-kDa type IV collagenase
24. Characteristics of 92 kDa type IV collagenase/gelatinase produced by granulocytic leukemia cells: Structure, expression of cDNA in E. coli and enzymic properties
25. The interglobular domain of cartilage aggrecan is cleaved by PUMP, gelatinases, and cathepsin B
26. Matrix metalloproteinases cleave at two distinct sites on human cartilage link protein
27. Identification of a stromelysin cleavage site within the interglobular domain of human aggrecan. Evidence for proteolysis at this site in vivo in human articular cartilage
28. Degradation of proteoglycan aggregate by a cartilage mettaloproteinase. Evidence for the involvement of stromelysin in the degradation of link protein heterogeneity in situ
29. Sites of stromelysin cleavage in collagen types II, IX, X, and XI of cartilage
30. Nonenzymatic glycation of type IV collagen and matrix metalloproteinase susceptibility
31. Matrix metalloproteinase-3 (stromelysin-1). Identification as the cartilage acid metalloprotease and effect of pH on catalytic properties and calcium affinity
32. Interaction of human rheumatoid synovial collagenase (matrix metalloproteinase 1) and stromelysin (matrix metalloproteinase 3) with human a2-macroglobulin and chicken ovostatin. Binding kinetics and identification of matrix metalloproteinase cleavage sites
33. Kinetics and physiologic relevance of the inactivation of alpha 1-proteinase inhibitor, alpha 1-antichymotrypsin, and antithrombin III by matrix metalloproteinases-1 (tissue collagenase), -2 (72-kDa gelatinase/type IV collagenase), and -3 (stromelysin)
34. A semicontinuous, high-performance liquid chromatography-based assay for stromelysin
35. Matrix metalloproteinases degrade insulin-like growth factor-binding protein-1 in dermal fibroblast cultures
36. Sites of nidogen cleavage by proteases involved in tissue homeostasis and remodelling
37. Limited cleavage of extracellular matrix protein BM-40 by matrix metalloproteinases increases its affinity for collagens
38. Different susceptibilities of fibulin-1 and fibulin-2 to cleavage by matrix metalloproteinases and other tissue proteases
39. Degradation of cross-linked fibrin by matrix metalloproteinase 3 (stromelysin 1): Hydrolysis of the gGly404-Ala405 peptide bond
40. Degradation of vitronectin by matrix metalloproteinases-1, -2, -3, -7, and -9
41. Direct activation of human neutrophil procollagenase by recombinant stromelysin
42. Biochemical characterization of human collagenase-3
43. Stepwise activation mechanisms of the precursor of matrix metalloproteinase 3 (stromelysin) by proteinases and 4-aminophenyl)mercuric acetate
44. Matrix metalloproteinase 3 (stromelysin) activates the precursor for the human matrix metalloproteinase 9
45. Mechanisms of activation of tissue procollagenase by matrix metalloproteinase 3 (stromelysin)
46. Cellular mechanisms for human procollagenase-3 (MMP-13) activation. Evidence that MT1-MMP (MMP-14) and gelatinase a (MMP-2) are able to generate active enzyme
47. Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage
48. Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage
49. Immunopheno-typing of childhood astrocytomas with a library of monoclonal antibodies
50. Immunoalkaline phosphatase cytochemistry
51. Diagnostic significance of levamisole-resistant alkaline phosphatase in cytochemistry and immunocytochemistry
52. The avidin-biotin reaction as an universal amplification system in immunoassays
53. Introduction to avidin-biotin technology
54. Prevention of nonspecific binding of avidin
55. The biotin-(strept)avidin system: Principles and applications in biotechnology
56. Extracellular matrix remodeling as a regulator of stromal-epithelial interactions during mammary gland development, involution and carcinogenesis
57. Roles of the matrix metalloproteinases in mammary gland development and cancer
58. Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response
59. Immunolocalization of matrix metallo-proteinases and their tissue inhibitor in human mammary pathology
60. Production of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human breast carcinomas
61. Sequential activation and production of matrix metalloproteinase-2 during breast cancer progression
62. Expression of matrix metalloprotease-9 in vascular pericytes in human breast cancer
63. Sequential production and activation of matrix-metalloproteinase-9 (MMP-9) with breast cancer progression
64. Matrix metalloproteinase-2 immunoreactive protein: A marker of aggressiveness in breast carcinoma
65. Matrix-metalloproteinases 1, 2, and 3 and their tissue inhibitors 1 and 2 in benign and malignant breast lesions: An in situ hybridization study
66. Tissue distribution of major matrix metalloproteinases and their transcripts in human breast carcinomas
67. Matrix metalloproteinase-1 and -3 in breast cancer: Correlation with progesterone receptors and other clinicopathologic features
68. MMP-2 positivity and age less than 40 years increases the risk for recurrence in premenopausal patients with node-positive breast carcinoma
69. Increased gelatinase-A and gelatinase-B activities in malignant vs. benign breast tumors
70. The matrix metalloproteinase stromelysin-1 acts as a natural mammary tumor promoter
71. CD44v(3,8-10) is involved in cytoskeleton-mediated tumor cell migration and matrix metalloproteinase (MMP-9) association in metastatic breast cancer cells
72. Enhanced expression of tissue inhibitor of metalloproteinase-2 (TIMP-2) in the stroma of breast carcinomas correlates with tumor recurrence
73. The expression of MMPs and TIMPs in human breast cancer tissues and importance of their balance in cancer invasion and metastasis
74. Gelatinase A/TIMP-2 imbalance in lymph-node-positive breast carcinomas, as measured by RT-PCR
75. TIMP-2 mediates cell surface binding of MMP-2
76. High levels of tissue inhibitor of metalloproteinase-1 predict poor outcome in patients with breast cancer
77. Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas
78. Biochemical characterization of human collagenase-3
79. Regulation of collagenase-3 expression in human breast carcinomas is mediated by stromal-epithelial cell interactions
80. Expression and regulation of collagenase-3 (MMP-13) in human malignant tumors
81. An overview of collagenase-3 expression in malignant tumors and analysis of its potential value as a target in antitumor therapies
82. Co-culture of human breast adenocarcinoma MCF-7 cells and human dermal fibroblasts enhances the production of matrix metalloproteinases 1, 2 and 3 in fibroblasts
83. A single set-related transcription factor, E1AF, confers invasive phenotype on human cancer cells
84. Genes involved in tumor invasion and metastasis are differentially modulated by estradiol and progestin in human breast-cancer cells
85. Epidermal growth factor and amphiregulin up-regulate matrix metalloproteinase-9 (MMP-9) in human breast cancer cells
86. Implication of collagen type I-induced membrane-type 1-matrix metalloproteinase expression and matrix metalloproteinase-2 activation in the metastatic progression of breast carcinoma
87. Induction of membrane-type matrix metalloproteinase 1 (MT1-MMP) expression in human fibroblasts by breast adenocarcinoma cells
88. Expression and tissue localization of membrane-types 1, 2, and 3 matrix metalloproteinases in human invasive breast carcinomas
89. Tyrosine phosphorylation mediates ConA-induced membrane type 1-matrix metalloproteinase expression and matrix metalloproteinase-2 activation in MDA-MB-231 human breast carcinoma cells
90. Calcium influx inhibits MT1-MMP processing and blocks MMP-2 activation
91. Immunological characterization of cell-surface and soluble forms of membrane type 1 matrix metalloproteinase in human breast cancer cells and in fibroblasts
92. Presence of high levels of MT1-MMP protein in fibroblastic cells of human invasive carcinomas
93. Significance of membrane type 1 matrix metalloproteinase expression in breast cancer
94. Role of cell surface metalloprotease MT1-MMP in epithelial cell migration over laminin-5
95. Elevated cyclic AMP suppresses ConA-induced MT1-MMP expression in MDA-MB-231 human breast cancer cells
96. Expression of MMP-2 and MMP-9, their inhibitors, and the activator MT1-MMP in primary breast carcinomas
97. Gelatinase A, membrane type 1 matrix metalloproteinase, and extracellular matrix metalloproteinase inducer mRNA expression: Correlation with invasive growth of breast cancer
98. Functional activation of integrin alpha V beta 3 in tumor cells expressing membrane-type 1 matrix metalloproteinase